Immunohistochemical assessment of NY-ESO-1 expression in esophageal adenocarcinoma resection specimens

被引:5
|
作者
Hayes, Stephen J. [1 ,2 ]
Hng, Keng Ngee [3 ]
Clark, Peter [1 ]
Thistlethwaite, Fiona [4 ]
Hawkins, Robert E. [5 ]
Ang, Yeng [2 ,3 ]
机构
[1] Salford Royal NHS Fdn Trust, Dept Histopathol, Salford M6 8HD, Lancs, England
[2] Univ Manchester, Fac Med & Human Sci, Manchester M13 9PL, Lancs, England
[3] Salford Royal NHS Fdn Trust, Dept Gastroenterol, Salford M6 8HD, Lancs, England
[4] Christie NHS Fdn Trust, Dept Med Oncol, Manchester M13 9PL, Lancs, England
[5] Univ Manchester, Paterson Inst Canc Res, Dept Med Oncol, Manchester M13 9PL, Lancs, England
关键词
Esophageal adenocarcinoma; Immunohisto-chemistry; NY-ESO-1; Stem cells; Vesicle trafficking; STEM-CELLS; BARRETTS METAPLASIA; ANTIGEN-EXPRESSION; EPITHELIUM; CANCER; ORIGIN;
D O I
10.3748/wjg.v20.i14.4011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To assess NY-ESO-1 expression in a cohort of esophageal adenocarcinomas. METHODS: A retrospective search of our tissue archive for esophageal resection specimens containing esophageal adenocarcinoma was performed, for cases which had previously been reported for diagnostic purposes, using the systematised nomenclature of human and veterinary medicine coding system. Original haematoxylin and eosin stained sections were reviewed, using light microscopy, to confirm classification and tumour differentiation. A total of 27 adenocarcinoma resection specimens were then assessed using immunohistochemistry for NY-ESO-1 expression: 4 well differentiated, 14 moderately differentiated, 4 moderatepoorly differentiated, and 5 poorly differentiated. RESULTS: Four out of a total of 27 cases of esophageal adenocarcinoma examined (15%) displayed diffuse cytoplasmic and nuclear expression for NY-ESO-1. They displayed a heterogeneous and mosaic-type pattern of diffuse staining. Diffuse cytoplasmic staining was not identified in any of these structures: stroma, normal squamous epithelium, normal submucosal gland and duct, Barrett's esophagus (goblet cell), Barrett's esophagus (non-goblet cell) and high grade glandular dysplasia. All adenocarcinomas showed an unexpected dot-type pattern of staining at nuclear, paranuclear and cytoplasmic locations. Similar dot-type staining, with varying frequency and size of dots, was observed on examination of Barrett's metaplasia, esophageal submucosal gland acini and the large bowel negative control, predominantly at the crypt base. Furthermore, a prominent pattern of apical (luminal) cytoplasmic dot-type staining was observed in some cases of Barrett's metaplasia and also adenocarcinoma. A further morphological finding of interest was noted on examination of haematoxylin and eosin stained sections, as aggregates of lymphocytes were consistently noted to surround submucosal glands. CONCLUSION: We have demonstrated for the first time NY-ESO-1 expression by esophageal adenocarcinomas, Barrett's metaplasia and normal tissues other than germ cells. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码:4011 / 4016
页数:6
相关论文
共 50 条
  • [31] NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches
    Baia, Gilson S.
    Caballero, Otavia L.
    Ho, Janelle S. Y.
    Zhao, Qi
    Cohen, Tzeela
    Binder, Zev A.
    Salmasi, Vafi
    Gallia, Gary L.
    Quinones-Hinojosa, Alfredo
    Olivi, Alessandro
    Brem, Henry
    Burger, Peter
    Strausberg, Robert L.
    Simpson, Andrew J. G.
    Eberhart, Charles G.
    Riggins, Gregory J.
    CANCER IMMUNOLOGY RESEARCH, 2013, 1 (05) : 296 - 302
  • [32] NY-ESO-1 protein expression and humoral immune responses in prostate cancer
    Fosså, A
    Berner, A
    Fosså, SD
    Hernes, E
    Gaudernack, G
    Smeland, EB
    PROSTATE, 2004, 59 (04): : 440 - 447
  • [33] NY-ESO-1:: Review of an immunogenic tumor antigen
    Gnjatic, Sacha
    Nishikawa, Hiroyoshi
    Jungbluth, Achim A.
    Guere, Ali O.
    Ritter, Gerd
    Jaeger, Elke
    Chen, Yao-Tseng
    Old, Lloyd J.
    ADVANCES IN CANCER RESEARCH, VOL 95, 2006, 95 : 1 - 30
  • [34] WT1, NY-ESO-1 AND PRAME EXPRESSION IN BREAST CANCER SUBTYPES
    Esposito, A.
    Bagnardi, V.
    Criscitiello, C.
    Gelao, L.
    Viale, G.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2014, 25 : 18 - 18
  • [35] NY-ESO-1 as a predictive and prognostic marker in NSCLC
    John, Tom
    Russell, Prudence
    Barnett, Stephen
    Wainer, Zoe
    White, Shane
    Mitchell, Paul
    Walkiewicz, Marzena
    Boutros, Paul C.
    Starmans, Maud H. W.
    Chen, Yao-Tseng
    Wright, Gavin
    Knight, Simon
    Cebon, Jonathan S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] NY-ESO-1 and clinicopathological features in ovarian cancer
    Topka, Charlotte R.
    ElMasri, Wafic M.
    Magyar, Clara E.
    Song, Min
    Dorigo, Oliver
    CANCER RESEARCH, 2012, 72
  • [37] The role of the NY-ESO-1 in the prognosis of gastric cancer
    Misir, Zvonimir
    Glavcic, Goran
    Jankovic, Suzana
    Kruljac, Ivan
    Cugura-Filipovic, Jaksa
    Cimiimic, Kristina
    Ulamec, Monika
    BIOMOLECULES AND BIOMEDICINE, 2024, 24 (04): : 813 - 820
  • [38] NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis
    Lai, Jin-Ping
    Robbins, Paul F.
    Raffeld, Mark
    Aung, Phyu Phyu
    Tsokos, Maria
    Rosenberg, Steven A.
    Miettinen, Markku M.
    Lee, Chyi-Chia Richard
    MODERN PATHOLOGY, 2012, 25 (06) : 854 - 858
  • [39] Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1
    Vaughan, HA
    Svobodova, S
    MacGregor, D
    Sturrock, S
    Jungbluth, AA
    Browning, J
    Davis, ID
    Parente, P
    Chen, YT
    Stockert, E
    St Clair, F
    Old, LJ
    Cebon, J
    CLINICAL CANCER RESEARCH, 2004, 10 (24) : 8396 - 8404
  • [40] Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues
    Wang, Xue-Yan
    Chen, Hong-Song
    Luo, Su
    Zhang, Heng-Hui
    Fei, Ran
    Cai, Jun
    ONCOLOGY REPORTS, 2009, 21 (03) : 713 - 719